Amifitadine

Amifitadine
Amifitadine
Systematic (IUPAC) name
(5S)-5-(3,4-dichlorocyclohexa-2,4-dien-1-yl)bicyclo[3.1.0]hexane
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code  ?
PubChem CID 11658655
ChemSpider 9833390 YesY
ChEMBL CHEMBL592374 YesY
Chemical data
Formula  ?
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Amifitadine, also known as DOV 21,947 or EB-1010, is an antidepressant drug being developed by Euthymics which is currently in clinical trials.[1] It is a so-called triple re/uptake inhibitor (TUI) aka SNDRI or scari.[1]

It is the (+)-enantiomer of DOV 216,303. IC50 values for SERT, NET, and DAT are Ki 99 nM, 262 nM, and 213 nM.[1]

It is closely related to DOV 102,677 and DOV 216,303.

DOV.gif
Com Uptake Binding
5-HT NE DA SERT NET DAT
216303 14 20 78 190 380 190
21947 12 23 96 100 260 210
102677 130 100 130 740 1000 220

Amifitadine reduces the duration of immobility in the forced swim test in rats with an oral minimum effective dose (MED) of 5 mg/kg. This anti-depressant-like effect manifests in the absence of significant increases in motor activity at doses of up to 20 mg/kg. DOV 21947 also produces a dose-dependent reduction in immobility in the tail suspension test, with an oral MED of 5 mg/kg.

References

  1. ^ a b c Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. (2003). "Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor". European journal of pharmacology 461 (2–3): 99–104. doi:10.1016/S0014-2999(03)01310-4. PMID 12586204.  edit